Canaccord Genuity
Canaccord Genuity is the global capital markets division of Canaccord Financial Inc. (CF : TSX | CF. : AIM), offering institutional and corporate clients idea-driven investment banking, research, sales and trading services.
The companies has operations in 24 cities worldwide and the ability to list companies on 10 stock exchanges.
View Older Stories View More Recent Stories
-
iAnthus to Present at Canaccord Genuity's Cannabis Investor Day
-
Obalon Therapeutics (OBLN) Terminates Offering of Common Stock After Whistleblower Contacts Auditor KPMG
-
Obalon Announces Termination of Public Offering of Common Stock
-
Obalon Announces Termination of Public Offering of Common Stock
-
Adobe (ADBE ) PT Raised to $220 at Canaccord Genuity
-
Netflix, Inc. (NFLX): Confident In Near And Mid Term Fundamentals - Canaccord
-
Netflix shares hit record high after blockbuster results
-
Histogenics (HSGX) Prices 2.34M Common Shares at $2.35/Sh
-
Histogenics Corporation Announces Pricing of Underwritten Registered Direct Offering of 2,340,430 Shares of Common Stock
-
Canada's small financial firms get buzz from weed stocks
-
TipRanks Identifies the Top 20 Analysts of 2017
-
Canaccord Tells Clients to 'stick with' Nuance Communications (NUAN), Could Retest Recent Highs
-
Captor Increases Size of Offering and Retains Canacord Genuity as Financial Advisor
-
Titan In Discussions With Braeburn Regarding U.S. Probuphine® Commercialization
-
Canaccord Genuity Resumes Neovasc (NVCN) at Buy
-
Atara Biotherapeutics (ATRA) PT Raised to $70 at Canaccord Genuity, 'see strong outcome for Phase 3 data based on prior studies'
-
Obalon Therapeutics (OBLN) Prices 5.45m Share Common Offering at $5.50/Sh
-
Obalon Therapeutics Prices Public Offering of Common Stock
-
Obalon Therapeutics Prices Public Offering of Common Stock
-
Thoma Bravo Acquires and Merges Motus and Runzheimer to Create Market Leading Vehicle Management Platform
-
Exact Sciences (EXAS) Selloff 'Overblown' Says Canaccord, 'We Would Aggressively Buy'
-
Biogen (BIIB) PT Raised to $350 at Canaccord Genuity on Lower Tax Rate; 'Remain Constructive Around Business Development'
-
Qualcomm (QCOM) PT Raised to $86 at Canaccord Genuity; 'Management Presents Case to Remain Independent, Introduces $1B Cost Reduction Program'
-
PlacementTracker Publishes 2017 PIPE and Private Placement Markets League Tables
-
NeuroMetrix (NURO), GlaxoSmithKline (GSK) Announce Strategic Collaboration to Develop and Expand Access to Quell Wearable Pain Relief Technology
-
Canaccord Genuity Downgrades Goldcorp (GG) to Hold
-
NeuroMetrix and GlaxoSmithKline Consumer Healthcare Announce Strategic Collaboration to Develop and Expand Access to Quell Wearable Pain Relief Technology
-
Canaccord Genuity Upgrades IAMGOLD (IAG) to Buy Following Investor Day
-
Obalon Therapeutics (OBLN) Commences $35M Offering of Common Stock
-
Obalon Therapeutics Announces Proposed Public Offering of Common Stock
-
Obalon Therapeutics Announces Proposed Public Offering of Common Stock
-
Razor Energy Corp. Announces Consolidation Acquisition in the Kaybob Area of West Central Alberta and Increased Term Loan Facility
-
CanniMed Therapeutics Inc. Launches $725 Million Lawsuit Alleging Multiple Claims of Wrongdoing Related to Aurora Hostile Bid
-
Alder Biopharm (ALDR) PT Raised to $22 at Canaccord Genuity; 'PROMISE 2 Results Better than Most Expected... Upside Potential for Possible 2H18 Filing for Eptinezumab'
-
Sequans Communications (SQNS): CES Confirms Turnaround Is On Track - Canaccord
-
AAR Corporation (AIR) PT Raised to $42 at Canaccord Genuity
-
Michael Barton joins Dalradian's Board of Directors
-
Helios and Matheson (HMNY) to Issue $60 Million in Convertible Notes
-
Helios and Matheson Analytics Inc. Enters Into Agreement to Issue $60 Million in Convertible Notes
-
Canaccord Genuity Downgrades Lipocine Inc (LPCN) to Hold
-
Nutritional High Announces Private Placement of $10 Million of Convertible Debenture Units Co-Led by Canaccord Genuity and Gravitas Securities
-
AltaGas Ltd. Announces Monthly Dividend
-
Steven Madden (SHOO): Pre-announcement Shows Consistency of Execution - Canaccord
-
Nektar Therapeutics (NKTR) PT Raised to $80 at Canaccord Genuity; 'NKTR-214 Opdivo combo data solidifying'
-
Steven Madden (SHOO) PT Raised to $51 at Canaccord Genuity
-
Canaccord Genuity Downgrades TiGenix NV (TIG) to Hold Following Acquisition
-
Canaccord Genuity Downgrades HudBay Minerals (HBM) to Hold Citing a Full Valuation
-
Canaccord Genuity Upgrades Hibbett Sports (HIBB) to Buy
-
RLJ Lodging Trust Names Ryan Meliker Senior Vice President of Corporate Strategy and Investor Relations
-
Sonic (SONC) PT Raised to $30 at Canaccord Genuity Following 1Q

